TB Archives – Treatment Action Group

The LAT CAB Responds to MedinCell and Medicines Patent Pool License on a New Long-Acting Malaria Formulation

September 21, 2022
Dorrit Walsh

As the global Long-Acting Technologies Community Advisory Board (LAT CAB) representing vast civil society networks, and people living with and affected by malaria, HIV, tuberculosis, and the hepatitis C virus (HCV) across the world, we welcome the efforts leading to the development of an investigational long-acting injectable (LAI) formulation of ivermectin to fight malaria transmission, mdc-STM currently in preclinical stage, and developed by MedinCell.

Treatment Action Group Statement on Retirement of Dr. Anthony S. Fauci

August 23, 2022
Dorrit Walsh

Treatment Action Group (TAG) meets with sadness the announcement by Dr. Anthony S. Fauci of his retirement as Director of the National Institute of Allergy and Infectious Diseases (NIAID), Chief of the NIAID Laboratory of Immunoregulation, and Chief Medical Advisor to President Biden, effective in December 2022.

Ten Principles for Access to Multi-disease Molecular Diagnostics: A Global Call to Action

August 23, 2022
Dorrit Walsh

Treatment Action Group (TAG) and Médecins Sans Frontières (MSF) Access Campaign are pleased to launch the Principles for Access to Multi-disease Molecular Diagnostics.

Treatment Action Group Adds Three New Board Members

August 23, 2022
Dorrit Walsh

As it celebrates its 30th Anniversary year, Treatment Action Group (TAG) announced the election of David Puente, Michael Montero and Ivy Kwan Arce to its Board of Directors.

Senior TB Project Associate

August 5, 2022
Dorrit Walsh

Treatment Action Group (TAG) is seeking a dynamic, highly motivated, and organized Senior TB Project Associate to support community engagement activities under the SMART4TB Project – a $200 million investment made by USAID to Support, Mobilize, and Accelerate Research for TB Elimination.

New Rifapentine Formulations at New Prices: No Excuses for Not Scaling-Up TB Preventive Treatment

August 1, 2022
Dorrit Walsh

We, the undersigned civil society and community-based organizations, welcome the announcement by Unitaid and its partners that they have reached an agreement with Lupin Limited and Macleods Pharmaceuticals to introduce two formulations of rifapentine at competitive prices.

1 / 4 / 6 x 24 Campaign Launched to Rally Energy, Political Will, Funding Needed to Fight Tuberculosis

July 31, 2022
Dorrit Walsh

Against the backdrop of the COVID-19 pandemic and other concurrent global health, economic, social, and political crises, the 1 / 4 / 6 x 24 Campaign, launched during the AIDS conference in Montreal, seeks to improve TB treatment and prevention worldwide based on the latest medical innovations and to reignite the fight to end tuberculosis (TB).

1 / 4 / 6 x 2024

July 25, 2022
Dorrit Walsh

Inspired by the legacy of Dr. Paul Farmer, the 1 / 4 / 6 x 24 Campaign calls for the "staff, stuff, space, systems and support" necessary to make groundbreaking short-course TB prevention and treatment regimens accessible to all who need them as a human right by the end of 2024.

Cover Of Pipeline Report 2022. Black Cover With Grey Type And Decorative Bright Green Lines

2022 Pipeline Report

July 24, 2022
Dorrit Walsh

Pipeline Report provides an overview of research and provides an overview of research and development of innovations for diagnosing, preventing, treating, and curing HIV, hepatitis C virus (HCV), and tuberculosis (TB).

Cover That Reads TB CAB 10-Year Anniversary Evaluation Report 2011-2021, March 2022, By Andrea DeLuca, Also Has A Black And Whilte Photo Montage Of People Engaged In Meetings And Demonstrations

TB CAB 10-Year Anniversary Evaluation Report 2011–2021 and Podcast

July 18, 2022
Dorrit Walsh

In 2021, the Global Tuberculosis Community Advisory Board (TB CAB) celebrated its tenth anniversary of advocating for community engagement in research and improved access to TB prevention, treatment, and diagnostic technologies.